tiprankstipranks
Advertisement
Advertisement

SGIOF Stock Latest News

Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise
Company AnnouncementsShionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise
9d ago
Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture
PremiumCompany Announcements
Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture
9d ago
Shionogi Secures ¥300 Billion Bridge Loan for Expanded ViiV Healthcare Stake
PremiumCompany Announcements
Shionogi Secures ¥300 Billion Bridge Loan for Expanded ViiV Healthcare Stake
14d ago
Shionogi Takes Full Control of Sleep Disorder JV in USD 100 Million Deal
PremiumCompany Announcements
Shionogi Takes Full Control of Sleep Disorder JV in USD 100 Million Deal
18d ago
Shionogi Secures ¥360 Billion Bridge Loan to Fund Global RADICAVA Rights Deal
PremiumCompany Announcements
Shionogi Secures ¥360 Billion Bridge Loan to Fund Global RADICAVA Rights Deal
18d ago
Shionogi Wins Japan Nod for XOCOVA as First Oral Post‑Exposure COVID‑19 Prophylactic
PremiumCompany AnnouncementsShionogi Wins Japan Nod for XOCOVA as First Oral Post‑Exposure COVID‑19 Prophylactic
18d ago
Shionogi Advances S-531011 Cancer Trial, Keeping Long-Term Upside in Play for SGIOF Investors
Premium
Company Announcements
Shionogi Advances S-531011 Cancer Trial, Keeping Long-Term Upside in Play for SGIOF Investors
23d ago
SGIOF
Shionogi Seeks Japan Approval for New CORECTIM Lotion for Atopic Dermatitis
Premium
Company Announcements
Shionogi Seeks Japan Approval for New CORECTIM Lotion for Atopic Dermatitis
1M ago
Shionogi’s S-606001 Pompe Trial: A Small Rare-Disease Bet With Big Upside Potential
PremiumCompany Announcements
Shionogi’s S-606001 Pompe Trial: A Small Rare-Disease Bet With Big Upside Potential
2M ago
SGIOF
Shionogi to Absorb Torii Pharmaceutical in 2027 to Boost Domestic Pharma Synergies
PremiumCompany Announcements
Shionogi to Absorb Torii Pharmaceutical in 2027 to Boost Domestic Pharma Synergies
2M ago
Shionogi’s Oral RSV Antiviral Moves Forward: What Investors Should Watch in This Phase 2b Trial
PremiumCompany Announcements
Shionogi’s Oral RSV Antiviral Moves Forward: What Investors Should Watch in This Phase 2b Trial
2M ago
SGIOF
Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook
PremiumCompany Announcements
Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook
2M ago
Shionogi Lifts Revenue and Profit on Royalty Growth and Overseas Expansion
PremiumCompany AnnouncementsShionogi Lifts Revenue and Profit on Royalty Growth and Overseas Expansion
2M ago
SGIOF Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
SGIOF Earnings this Week: How Will it Perform?
2M ago
Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
Premium
Company Announcements
Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
3M ago
Shionogi Buys Global RADICAVA Rights in $2.5 Billion ALS Drug Deal to Build Rare Disease Platform
PremiumCompany Announcements
Shionogi Buys Global RADICAVA Rights in $2.5 Billion ALS Drug Deal to Build Rare Disease Platform
4M ago
Shionogi Wins Japan Approval for Rapid-Acting Depression Drug ZURZUVAE
PremiumCompany Announcements
Shionogi Wins Japan Approval for Rapid-Acting Depression Drug ZURZUVAE
4M ago
Shionogi Completes Acquisition of Japan Tobacco’s Pharmaceutical Business
PremiumCompany Announcements
Shionogi Completes Acquisition of Japan Tobacco’s Pharmaceutical Business
4M ago
Shionogi Announces Corrections to Q2 2025 Financial Results
PremiumCompany Announcements
Shionogi Announces Corrections to Q2 2025 Financial Results
4M ago
Shionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion
PremiumCompany AnnouncementsShionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion
5M ago
Shionogi & Co. Adopts New Management Policies to Enhance Capital and Stock Awareness
Premium
Company Announcements
Shionogi & Co. Adopts New Management Policies to Enhance Capital and Stock Awareness
6M ago
Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges
Premium
Company Announcements
Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >